We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
69 hedge funds and large institutions have $111M invested in Crescent Biopharma in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 23 increasing their positions, 9 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
156% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 9
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
75% more call options, than puts
Call options by funds: $3.4M | Put options by funds: $1.95M
33% more capital invested
Capital invested by funds: $82.9M → $111M (+$27.6M)
19% more funds holding
Funds holding: 58 → 69 (+11)
0.03% more ownership
Funds ownership: 0.55% → 0.57% (+0.03%)
Holders
69
Holders Change
+11
Holders Change %
+18.97%
% of All Funds
0.99%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
23
Reduced
9
Closed
10
Calls
$3.4M
Puts
$1.95M
Net Calls
+$1.45M
Net Calls Change
+$1.14M
Top Buyers
| 1 |
Millennium Management
New York
|
+$2.12M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.32M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.02M |
| 4 |
Jane Street
New York
|
+$694K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$643K |
Top Sellers
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$2.78M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$629K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$546K |
| 4 |
Two Sigma Advisers
New York
|
-$407K |
| 5 |
AO
Advisor OS
Chicago,
Illinois
|
-$238K |
